ContraFect (NASDAQ: CFRX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “ContraFect released 2Q21 earnings that were largely in line with expectations, but more importantly, disclosed that they are now seeing effects of the pandemic on the Phase 3 DISRUPT trial in terms of the monthly … Continue reading InvestorNewsBreaks – ContraFect Corp. (NASDAQ: CFRX) Featured in Mizuho Securities Research Report